Abstract: The invention relates to polyoxyalkylenes having pendant long-chain acyloxy radicals and to a process for preparation thereof by an alkoxylation reaction using double metal cyanide (DMC) catalysts.

Abstract: Methods of forming olyurethane foams that are the reaction product of at least one polyisocyanate and a polyol composition are provided. The polyol composition includes at least one natural oil based polyol and at least one poly(propylene oxide) polyol and is desirably free of non-natural oil based polyols made from alkylene oxide units, other than propylene oxide units. The natural oil based polyol is present in a quantity sufficient to increase the processing window for the foam relative to a foam made using the same process and the same components, absent the natural oil based polyol. As a result, the present foams can provide very open-cellular structures with the superior performance properties of a poly(propylene oxide) polyol-based foam.

Abstract: The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms.

Abstract: The invention relates to fatty acid acylated salicylate derivatives; compositions comprising an effective amount of a fatty acid acylated salicylate derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a fatty acid acylated salicylate derivative.

Abstract: The invention relates to polyesterols obtainable by reaction of b1) from 10 to 70 mol % of at least one compound selected from the group consisting of terephthalic acid, dimethyl terephthalate, polyethylene terephthalate, phthalic anhydride, phthalic acid and isophthalic acid, b2) from 0.8 to 4.5 mol % of a fatty acid triglyceride, b3) from 10 to 70 mol % of a diol selected from the group consisting of ethylene glycol, diethylene glycol and polyethylene glycols, b4) from 5 to 50 mol % of a polyether polyol having a functionality above 2, wherein at least 200 mmol of component b4) are used per kg of the polyesterol, wherein the sum total of components b1) to b4) is 100 mol %.

Abstract: Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R?C(0); —OC(O)— or —CH(OH)—; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A and B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=1-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and/or renal disorders complications, or (iv) fibrosis-related organ dysfunction.

Abstract: The invention relates to a process for preparing chiral octenoic acid derivatives, which constitute important intermediates in the preparation of medicament active ingredients, and also to novel intermediates which are used in the process for preparing the octenoic acid derivatives mentioned.

Abstract: Plasticizers are made from oil with a narrowed, fatty acid polydispersity and extracted from a microorganism, such as a natural or genetically modified bacterium or algae. These plasticizers can comprise either a large content of either saturated C4 and/or C6 triglycerides or unsaturated C12 or greater triglycerides that have been chemically modified by one or more of epoxidation, acylation and esterification. The plasticizers of this invention are particularly well-suited for use with polar polymeric resins such as PVC.

Abstract: Provided are compounds for inhibiting Snail-p53 binding and therapeutic agents for cancer including the compounds as an effective component. The Snail-p53 binding inhibitors induce expression of p53 in K-Ras mutant cell lines, thereby enabling effective treatment or prevention of K-Ras mutant cancer, such as, pancreatic cancer, lung cancer, cholangioma, and colon cancer, of which diagnosis or treatment is not easy.

Abstract: The present invention is aimed at a process for obtaining oreganic acid and derivatives thereof, to the intermediate compounds of this synthesis and to the use of

Abstract: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.

Abstract: The present invention deals with the certain castor polyesters which give high gloss when applied to the skin. The ester are the reaction of the hydroxyl group of castor oil with less than one equivalent of a fatty acid then in a subsequently step the remainder of an equivalent of a diacid.

Abstract: This invention relates to a novel 2-hydroxypropionic acid derivative and its manufacturing method. Based on its mechanism to inhibit the CPT I, 2-hydroxypropionic acid derivative of this invention has blood glucose lowering effects so that the derivative may be effectively used as an antidiabetic agent having remarkable antidiabetic activity and fewer side effects.

Abstract: Novel nonionic gemini surfactants are extremely effective emulsifiers for oil-in-water emulsions that provide improved detergency at even low concentration levels. The surfactants are characterized by the formula: ##STR1## wherein R.sub.1 is independently H or a C.sub.1 to C.sub.22 alkyl, R.sub.2 is H or C.sub.1 to C.sub.22 alkyl and R.sub.3 is D.sub.1 --R.sub.4 --D.sub.1 or R.sub.4 --D.sub.1 --R.sub.4 wherein R.sub.4 is independently a C.sub.1 -C.sub.10 alkyl group, --C(O)--, --R.sub.5 ?O(EO).sub.a (PO).sub.b !--, --O--R.sub.5 --O--, or aryl, e.g. phenyl, and D.sub.1 is independently --O--, --S--, --S--S--, --SO.sub.2 --, --C(O)--, a polyether group ?--O(EO).sub.a (PO).sub.b --!, an amide group ?--C(O)N(R.sub.6)--!, an amino group ?--N(R.sub.6)--!, --O--R.sub.5 --O--, or aryl. (EO).sub.a (PO).sub.b is a polyether group and Z is a C.sub.1 -C.sub.

Abstract: The composition and methods of synthesis of phosphorus prodrugs are described. These methods can be used to convert negatively charged phosphorous bearing drugs into neutrally charged; lipid soluble prodrugs which are able to passively diffuse into cells and into tissues in vivo. Prodrugs for a variety of antiviral and anti-leukemic agents are described.

Abstract: Novel acyclic terpene compounds useful as intermediates for producing sarcophytol A which have an anti-carcinogenic promotor activity and anti-tumor activity, which compounds are shown by the following general formula (I): ##STR1## [wherein R.sup.1 is a hydrogen atom, 1-alkoxyalkyl group, tetrahydrofuryl group, tetrahydropyranyl group or acyl group; R.sup.2 is a group of formula: --CHO, --CH.sub.2 OR.sup.3 or ##STR2## (wherein R.sup.3 is a hydrogen atom, 1-alkoxyalkyl group, tetrahydrofuryl group, tetrahydropyranyl group or acyl group; and R.sup.4 is C.sub.1 to C.sub.4 alkyl group) with the proviso that R.sup.1 and R.sup.3 do not represent the same substituents simultaneously; when R.sup.1 is a hydrogen atom, R.sup.3 is not acetyl group or tetrahydropyranyl group; and when R.sup.2 is a group of formula: ##STR3## R.sup.1 is not a hydrogen atom).

Abstract: New cholesterol lowering compounds are formed from the photochemical treatment of zaragozic acid A.

Abstract: The invention relates to compounds containing carbonate groups and carbonyl groups and having the general formula ##STR1## in which R stands for a C.sub.1 -C.sub.4 -alkyl radical, an aryl radical, or a radical R.sup.1, whereR.sup.1 has the following formula ##STR2## in which R.sup.2 to R.sup.6 stand for H, alkyl, OH, O-alkyl, SH, S-alkyl, halogen, N(alkyl).sub.2, or N(alkyl)(aryl) and at least one but not more than three of the radicals R.sup.2 to R.sup.6 stand for a radical of the formula ##STR3## in which A, B and C stand for alkylene, cycloalkylene, oxaalkylene, polyoxaalkylene or arylene, k and l both stand for an integer from 1 to 80, and the end group Z stands for alkyl, aryl, alkoxycarbonyl, alkoxycarbonyloxy, or aryl.These compounds are suitable for use as emulsifiers for dispersions.

Abstract: This invention relates to methods for producing optically active hydroxyesters and also to methods for producing and purifying optically active five-membered ring lactones.More specifically, the invention provides methods for efficiently, safely, and selectively producing and purifying optically active (R)-hydroxyester (shown by formula 1) and optically active (S)-hydroxyester (shown by formula 2) in high state of purity at ordinary temperature.The invention also relates to application of the interconvertible optically active (R)-five-membered ring lacton (shown by formula 5).They are intermediates for synthesizing various medicines, agricultural chemicals, and biologically active substances, however especially useful for synthesizing pheromone of a noxious insect, Popillia japonica Newman. ##STR1## (Here, R.sub.1 denotes --C.tbd.C--R.sub.3 or --C.dbd.C--R.sub.3 ; R.sub.2 and R.sub.3 denote straight chain or branched alkyl groups containing 1 to 10 carbon atoms; R.sub.

Abstract: Process for the preparation of ester polyols by conducting the ring opening of epoxidized esters and/or alcohols with carboxylic acids by the controlled addition of the epoxidized compounds to the carboxylic acids wherein the carboxylic acids are present in at least stoichiometric quantities based on epoxide groups, to minimize unreacted epoxide groups and produce ester polyols having relatively low viscosities compared to those produced by the one-pot prior art process.

Abstract: Aryl alkenoic acid derivatives, and physiologically acceptable salts thereof, are provided which are potent leukotriene antagonists and may be used for the treatment of circulatory diseases and preferably for respiratory diseases such as asthma. The derivatives have a general formula I ##STR1## in which X is --S--,W is CH.dbd.CH;o is 1 to 4;n is 2 to 6;m is 0 to 2;T and Z, same or different, represent oxygen or a direct bond;R.sup.2 and R.sup.3, represent hydrogen, or fluorine;A represents carboxyl, CO.sub.2 R.sub.4.sup.4, wherein R.sup.4 is lower alkylR is ##STR2## wherein Y represents carboxyl, CO.sub.2 R.sup.4, wherein R.sup.4 is lower alkylR.sup.7 and R.sup.8, same or different, represent H or lower alkyl;R.sup.9 represents --OH, --O-alkyl, NH.sub.2 or a NHCH.sub.2 CO.sub.2 H group; andR.sup.10 R3 is H.

Abstract: The present invention is novel compounds, which are derivatives of 4'-hydroxyphenylacetic acid having antiinflammatory activity for the treatment of arthritis, asthma, Raynaud's disease, inflammatory bowel disorders, trigeminal or herpetic neuralgia, inflammatory eye disorders, psoriasis, and having analgesic activity. Particularly, the analgesia may be useful for the treatment of dental pain and headache, especially vascular headache, such as migraine, cluster and mixed vascular syndromes, as well as nonvascular tension headache.

Abstract: There are disclosed 3-substituted and 3,3-disubstituted all-trans-4-oxoretinoic acids and 3-substituted and 3,3-disubstituted 13-cis-4-oxoretinoic acids and their lower alkyl esters.